IM Cannabis (IMCC) versus Its Rivals Financial Survey

IM Cannabis (NASDAQ:IMCC) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare IM Cannabis to similar businesses based on the strength of its valuation, dividends, risk, profitability, institutional ownership, analyst recommendations and earnings.

Insider & Institutional Ownership

7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 5.9% of IM Cannabis shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares IM Cannabis and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IM Cannabis	-39.62%	N/A	-58.32%
IM Cannabis Competitors	-2,393.19%	-220.45%	-16.12%

Volatility & Risk

IM Cannabis has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500. Comparatively, IM Cannabis’ rivals have a beta of -0.05, indicating that their average share price is 105% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for IM Cannabis and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IM Cannabis	1	0	0	0	1.00
IM Cannabis Competitors	7819	13782	25790	1035	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.74%. Given IM Cannabis’ rivals stronger consensus rating and higher possible upside, analysts plainly believe IM Cannabis has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares IM Cannabis and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
IM Cannabis	$39.17 million	-$8.10 million	-0.01
IM Cannabis Competitors	$3.54 billion	$3.17 billion	553.74

IM Cannabis’ rivals have higher revenue and earnings than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

IM Cannabis rivals beat IM Cannabis on 10 of the 13 factors compared.

About IM Cannabis

IM Cannabis Corp. (NASDAQ: IMCC) is a medical cannabis company focused primarily on the Israeli and German markets. The company develops, sources, imports, distributes and markets medical cannabis products under the IMC brand, serving patients through pharmacies, clinics and other authorized channels. In Israel, IM Cannabis is involved in the supply of medical cannabis products, including flower and other cannabis-based offerings, through affiliated cultivation, processing and distribution operations.